Sobi (Swedish Orphan Biovitrum AB)
(https://synagis.com) 📸 Data Snapshot: June 19, 2026
Information Density — The Lens
Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
Info Density
Power-words vs. Substance ratio.
19
Impact Weight: 30 / 100
63% Reputation
The site maintains a relatively high substance-to-fluff ratio, citing specific medical conditions like Diffuse Large B-Cell Lymphoma and Haemophilia. However, headings like ‘We transform everyday life’ and ‘Unlocking the potential of breakthrough therapies’ utilize high-saturation power words without immediate specific nouns. The inclusion of the 5% metric for approved rare disease medicines provides necessary grounding in an otherwise aspirational hero section.
Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.
📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE (https://synagis.com) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
SUB-PAGE (https://synagis.com/middle-east/en/) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
SUB-PAGE (https://synagis.com/en/pipeline/) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
SUB-PAGE (https://synagis.com/en/careers/) Sobi – Transforming the lives of people with rare diseases
[H1] We transformeveryday life for people living with rare diseases More about us We are unlocking the potential of breakthrough therapies Join us OUR SCIENCE | R&D [H3] Innovative medicines in the pipeline Only 5 % of rare diseases have approved medicines. The need for innovative treatments is, therefore, high. A strong pipeline and expanded access are key elements of our commitment to patients. View pipeline RESULTS CENTRE [H3] Financial reports Sobi intends to publish its Q2 2026 report on 16 July 2026.Aide memoire Financial reports MEDIA | PRESS RELEASES [H3] Press releases 11 June, 2026 08:00 Sobi to present new clinical and real-world data at EHA 2026 in Stockholm 1 June, 2026 10:00 Sobi to present new data on pegcetacoplan at ERA 2026 Learn more News [H3] Focus on sustainability Sobi celebrates meaningful progress on its climate journey – from validated science-based targets to rising use of renewable electricity and fossil-free car fleets across several countries. Our climate progress RARE DISEASES [H3] Focus on Rare diseases More than 10,000 rare diseases have been identified, with more being discovered every day. While many rare diseases are very uncommon, together they affect 400 million people worldwide. Rare diseases INNOVATIVE TREATMENTS [H3] A new therapy’s path to the patient Bringing new therapies to patients involves navigating long timelines and inherent risks, making it a complex and costly endeavor. Discover how we prioritise patient access to treatment while addressing these development challenges. From lab to patient [H3] Our stories At Sobi, we are dedicated to transforming the lives of people with rare and debilitating diseases. Meet some of the people who inspire us.Their real-life experiences and stories reinforce our commitment to patients. Read the stories Haematology [H5] Living with Diffuse Large B-Cell Lymphoma Haematology [H5] Diagnose Diffuse Large B-Cell Lymphoma Haemophilia [H5] A decade of dedication: Transforming haemophilia care through global collaboration Haemophilia [H5] Sustainable progress in Dominican Republic thanks to WFH Humanitarian Aid Program Haematology [H5] Diagnosis and donations to enable sustainable care in Cambodia Share price Loading... Share information [IMG: Sobi_HQ_office_building-cut.jpg] [H3] Head office [email protected] +46 8 697 20 00 Visiting address: Norra Stationsgatan 93A Stockholm, Sweden Global contacts [H3] Careers Take a look at our job opportunities. Join us English Swedish Global Global Global contacts Europe Austria Belgium NL Belgium FR Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Italy Latvia Lithuania Luxembourg Malta Norway Poland Portugal Romania Russia Slovakia Slovenia Spain Sweden Switzerland DE Switzerland FR The Netherlands Turkey United Kingdom Middle East & Africa Algeria Bahrain Egypt Iraq Jordan Kuwait Lebanon Libya Middle East Morocco Qatar Oman Saudi Arabia Tunisia United Arab Emirates Asia Pacific Australia China Japan North America USA Canada Close Close
3733 chars
🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against
Generic Claims:
advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes, pioneering medical science, the future of medicine…
Red Flags:
FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified, patient testimonials making efficacy claims, off-label promotion signals…
Semantic Drift Patterns:
homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations:
specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations, specific patent numbers and status, pharmacovigilance and adverse event reporting mechanisms…
Explore the other reputation pillars for Sobi (Swedish Orphan Biovitrum AB)
Analysis Disclosure & Source Attribution
This page presents a snapshot of public data from Sobi (Swedish Orphan Biovitrum AB), captured on June 19, 2026, to show how machine logic reads Information Density signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Sobi (Swedish Orphan Biovitrum AB): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://synagis.com to view the most current version of its content and see directly what this company is about and what it offers.